San Clemente, Calif. — November 4, 2025 — Leads & Copy — Sofwave Medical Ltd (TASE: SOFW) announced its third-quarter results for fiscal year 2025, reporting record quarterly revenue of $21.1 million, a 56% year-over-year increase, and an IFRS gross margin of 73.7%.
The company’s third-quarter pulse recurring revenue was $8.3 million, up 55% year-over-year. First nine months revenue reached $58.7 million, a 42% increase, with an IFRS gross margin of 75.1%. IFRS and non-IFRS net income for the first nine months were $1.4 million and $3.2 million, respectively, compared to a net loss in the same period last year.
Approximately 667,000 pulse treatments have been administered since commercialization. The company expects to achieve net profitability in 2025.
According to Sofwave CEO Louis Scafuri, the company delivered exceptional third-quarter results, achieving record revenue during what is historically the med-device aesthetics industry’s slowest quarter. Chairman & Co-Founder Dr. Shimon Eckhouse added that the company’s record quarterly revenue is a testament to its disruptive technology and the value it delivers to patients and providers alike.
Recent operational highlights include FDA pre-market clearance for the Pure Impact VIP™ standalone EMS device and a company expectation to achieve net profitability in 2025.
Contact: Info@sofwave.com
Investor Contact:
Brian Ritchie
LifeSci Advisors LLC
(212) 915-2578
britchie@lifesciadvisors.com
